23andMe Clarifies Customer Data Protections Amid Asset Sale Process
SAN FRANCISCO, April 18, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (OTC: MEHCQ), a prominent player in the human genetics and biotechnology sector, has provided important updates regarding the measures in place to protect customer data during the court-supervised sale of its assets. This process is being conducted by the Special Committee of the Companys Board of Directors, which is responsible for evaluating potential acquisition bids, and is under the supervision of the U.S. Bankruptcy Court for the Eastern District of Missouri. This court acts as an independent authority, tasked with reviewing and approving any sale transactions to ensure their legitimacy and compliance with applicable laws.
A crucial aspect of this bidding process is the regulatory review that any potential bidders must undergo. The capability of a bidder to effectively complete a transaction and navigate required regulatory approvals swiftly is of paramount importance. This includes adherence to the Hart-Scott-Rodino Act and securing necessary approvals from the Committee on Foreign Investment in the United States. Notably, the Company has declared that it will not accept bids from entities situated inor with substantial investments fromcountries that pose national security concerns. These nations include China, Cuba, Iran, North Korea, Russia, and Venezuela, reflecting the Companys commitment to safeguarding customer privacy and ensuring compliance with relevant regulations.
In the context of the bidding procedures, 23andMe mandates all interested parties to guarantee compliance with the Companys privacy policies and relevant legal frameworks. Bidders are also required to provide comprehensive insights into their intended use of any acquired customer data. They must outline the privacy programs and security measures currently in place or planned for implementation, as well as disclose any proposed changes to existing privacy policies. Such modifications, if any, must adhere strictly to the Company's established privacy policies and the legal standards.
In an effort to further enhance data protection, 23andMe has filed a motion seeking the appointment of an independent Customer Data Representative (CDR). If the Court approves this motion, the CDR will serve as a neutral third party tasked with evaluating whether any proposed transactions are compliant with the companys privacy policies and relevant data privacy laws, thereby ensuring the security of customer information.
23andMe is deeply committed to its role as a protector of customer data. The Company upholds stringent data privacy and security protocols, complying with various consumer and genetic privacy laws. With a focus on transparency, 23andMe extends its safeguards to customers worldwide, striving to exceed the conventional standards set by the healthcare industry.
For more detailed information concerning 23andMes Chapter 11 filing, proceedings, and claims process, interested parties can visit
Hana Takahashi
